PTGS2 and colonic neoplasm: Because COX-2 selective inhibition has been shown to possess antineoplastic properties with few adverse GI events, the use of these agents may potentially represent a novel therapeutic approach to reduce the risk of colon cancer associated with hypergastrinaemia.